- Previous Close
0.3197 - Open
0.3197 - Bid 0.3197 x --
- Ask 0.3660 x --
- Day's Range
0.3197 - 0.3197 - 52 Week Range
0.3000 - 1.1100 - Volume
2,500 - Avg. Volume
21,565 - Market Cap (intraday)
1.552M - Beta (5Y Monthly) 0.95
- PE Ratio (TTM)
-- - EPS (TTM)
-34.5100 - Earnings Date Apr 3, 2025 - Apr 8, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
www.panbela.comRecent News: PBLA
View MorePerformance Overview: PBLA
Trailing total returns as of 4/1/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PBLA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PBLA
View MoreValuation Measures
Market Cap
1.60M
Enterprise Value
7.85M
Trailing P/E
0.00
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-229.77%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-37.05M
Diluted EPS (ttm)
-34.5100
Balance Sheet and Cash Flow
Total Cash (mrq)
4.73M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-7.98M